	US 12,264,184 B2
	DAP12 constructs and their use to enhance DC vaccines and immunotherapies
Erika A. Eksioglu, Tampa, FL (US)
Assigned to H. Lee Moffitt Cancer Center and Research Institute, Inc., Tampa, FL (US)
Filed by H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC., Tampa, FL (US)
Filed on Feb. 23, 2022, as Appl. No. 17/678,565.
Claims priority of provisional application 63/152,378, filed on Feb. 23, 2021.
Prior Publication US 2023/0062550 A1, Mar. 2, 2023
Int. Cl. C07K 14/47 (2006.01); A61K 35/15 (2015.01); A61K 38/17 (2006.01); A61K 39/00 (2006.01); A61K 45/06 (2006.01); A61P 35/00 (2006.01); C12N 5/0783 (2010.01); C12N 5/0784 (2010.01)

CPC C07K 14/4705 (2013.01) [A61K 38/1709 (2013.01); A61K 39/4615 (2023.05); A61K 39/4622 (2023.05); A61K 39/46449 (2023.05); A61K 45/06 (2013.01); A61P 35/00 (2018.01); C12N 5/0636 (2013.01); C12N 5/0639 (2013.01); A61K 2239/31 (2023.05); A61K 2239/38 (2023.05); A61K 2239/57 (2023.05); C12N 2501/998 (2013.01)]

23 Claims

1. A modified 12-kilodalton DNAX activating protein (DAP12) comprising one or more substitutions in the cytoplasmic domain of DAP12; wherein the one or more substitutions occurs at a residue corresponding to residues 91, 99, 100, 101, 102, 104, 105, 106, 111, or 112 of DAP12; wherein at least one substitution comprises an asparagine to lysine substitution at residue 106 (N106K).